renal cell carcenoma

An antigen has just been tested in a vaccine treatment on RCC with great results in pre clinicals. These new class of vaccines that fight cancer after it is found, dont cure the cancer but prolong life without the nasty side effects of chemos.
Probably be a great fit with Coramsine.

"Dendreon Presents Data at American Association of Immunology Conference Highlighting Potential New Active Immunotherapy for Treatment of Renal Cell Cancer

SEATTLE and BOSTON, May 15, 2006 − Dendreon Corporation (Nasdaq: DNDN) today announced preclinical data demonstrating that active immunotherapy using Dendreon's proprietary Antigen Delivery Cassette(TM) technology with the antigen carbonic anhydrase IX (CA9), a well-validated and highly-expressed target in renal cell carcinoma (RCC), significantly prolonged survival in RCC animal models. The abstract entitled, "Active Cellular Immunotherapy using CA9-GM-CSF Fusion Protein: A Potent Antigen for Active Immunotherapy," was presented here today at the American Association of Immunology Conference.

Dendreon scientists showed that antigen presenting cells exposed to the CA9 Antigen Delivery Cassette and injected into mice led to a significant prolongation in survival in animals challenged with CA9 expressing tumors. This effect appeared to be sustained with 40 percent of the animals in the drug arm alive at the end of the study compared to zero percent of the animals in the control arm (p-value = .008). The data presented also showed that immunization of mice transgenic for the human HLA-DR4 gene with the CA9 Antigen Delivery Cassette protein could induce CA9-specific T-cells that were restricted to HLA-DR4.

"These results suggest that CA9 is a potent antigen for active immunotherapy," said David Urdal, Ph.D., chief scientific officer of Dendreon Corporation. "These preclinical results are compelling and consistent with the data we have seen with our other immunotherapy products PROVENGE and NEUVENGE and may lead to the development of a third compelling product candidate utilizing our Antigen Delivery Cassette technology."

About CA9

More than 75 percent of primary and metastatic RCCs highly express the transmembrane protein carbonic anhydrase IX, or CA9. In addition, CA9 is expressed in other cancers such as non-small cell lung and breast tumors but not in normal tissue. "